thiethylperazine (torecan) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Thiethylperazine is a antiemetic, which was used for the treatment of nausea and vomiting in patients undergoing radiotherapy, chemotherapy or as a postoperative care. Thiethylperazine exerts its therapeutic effect by blocking dopamine receptors in brain. The drug is capable of potentiating CNS depressants as well as atropine.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10h-phenothiazine | ethylthioperazine | gs-95 | norzine | thiethylperazin | thiethylperazine | thiéthylpérazine | thiethylperazine dimalate | thiethylperazine malate | thiethylperazine maleate | thiethylperazinum | thietylperazine malate | thietylperazine maleate | tietilperazina | torecan

Organizations (6)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (2)


 

Nausea (approved 1961)

Vomiting (approved 1961)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue